<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nearly 100% of Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e>) and 5% to 8% of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e>) harbor a balanced translocation involving c-MYC </plain></SENT>
<SENT sid="1" pm="."><plain>Although characteristic morphologic and immunophenotypic features can identify <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> in most cases, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with atypical features are often encountered in clinical practice </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, no morphologic or immunophenotypic finding can predict an underlying c-MYC translocation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> with certainty </plain></SENT>
<SENT sid="3" pm="."><plain>Here we report on a novel monoclonal antibody recognizing the c-myc protein in formalin-fixed, paraffin-embedded tissue which we used to evaluate a spectrum of aggressive B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> by standard immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>Cases consisted of 17 BLs (15 cases with confirmed c-MYC translocation), 19 DLBCLs without a c-MYC translocation, 5 DLBCLs with a c-MYC translocation, and 2 B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, unclassifiable, with features intermediate between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> (intermediate DBLCL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, one case with c-MYC translocation and one case without a c-MYC translocation) </plain></SENT>
<SENT sid="5" pm="."><plain>The intensity and subcellular localization of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific staining for c-myc protein was determined independently by 2 pathologists and in a blinded fashion for each case </plain></SENT>
<SENT sid="6" pm="."><plain>We observed c-myc expression in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells of <z:hpo ids='HP_0000001'>all</z:hpo> cases regardless of c-MYC status </plain></SENT>
<SENT sid="7" pm="."><plain>Among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e>, c-myc protein primarily localized to the nucleus of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in 15 of 17 cases (88%) and equally localized to the nucleus and cytoplasm of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in 2 of 17 cases (12%) </plain></SENT>
<SENT sid="8" pm="."><plain>In no case did c-myc protein primarily localize to the cytoplasm </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> lacking a c-MYC translocation the c-myc protein primarily localized to the cytoplasm of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in 18 of 19 cases (95%) and equally localized to the nucleus and cytoplasm in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in 1 of 19 cases (5%) </plain></SENT>
<SENT sid="10" pm="."><plain>In no case did c-myc protein primarily localize to the nucleus </plain></SENT>
<SENT sid="11" pm="."><plain>Among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> with a c-MYC translocation and intermediate DBLCL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e>, the c-myc protein primarily localized to the nucleus, or equally localized to the nucleus and cytoplasm of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in 4 of 5 cases (80%) and 2 of 2 cases (100%), respectively </plain></SENT>
<SENT sid="12" pm="."><plain>Taken together, we find that a primarily nuclear or mixed nuclear and cytoplasmic staining pattern for c-myc in an aggressive B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is highly predictive of a c-MYC translocation (positive-predictive value=0.92, negative-predictive value=0.95, P&lt;0.0001) </plain></SENT>
<SENT sid="13" pm="."><plain>We further show that the subcellular localization of c-myc can be determined with good interobserver agreement among pathologists (kappa statistic=0.90) </plain></SENT>
<SENT sid="14" pm="."><plain>Thus this novel immunohistochemsitry test is a useful tool for identifying aggressive B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> likely to harbor a c-MYC rearrangement and thus warrant genetic testing </plain></SENT>
</text></document>